Registered title, quoted from ClinicalTrials.gov
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07328802, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed, surgically unresectable locally advanced or metastatic cholangiocarcinoma.
Inclusion criterion 3
No prior systemic therapy; subjects who completed postoperative adjuvant therapy **>6 months ago** are eligible.
Inclusion criterion 4
Prior anti-angiogenic therapy (e.g., bevacizumab). 8. Active bleeding within 3 months prior to first dose:
Exclusion criterion 12
ECOG PS score 0 or 1.
Inclusion criterion 7
HBsAg-positive AND HBV-DNA > local ULN;
Exclusion criterion 20
At least one measurable lesion per RECIST 1.1 criteria.
Inclusion criterion 6
Other malignancies within 5 years prior to first dose (excluding radically cured basal cell carcinoma, squamous cell carcinoma of skin, or carcinoma in situ).
Exclusion criterion 1
HIV infection (HIV 1/2 antibody-positive). 20. Untreated active HBV:
Exclusion criterion 19
Surgically sterilized/hysterectomy. 10. All subjects (regardless of gender) at conception risk must use contraception with <1% annual failure rate during treatment and for 120 days after last dose.
Inclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07328802, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Signed written informed consent prior to any trial-related procedures.
- Male or female aged **≥18 years and ≤75 years**.
- Histologically or cytologically confirmed, surgically unresectable locally advanced or metastatic cholangiocarcinoma.
- No prior systemic therapy; subjects who completed postoperative adjuvant therapy **>6 months ago** are eligible.
- Life expectancy >3 months.
- At least one measurable lesion per RECIST 1.1 criteria.
- ECOG PS score 0 or 1.
- Adequate organ function (all laboratory criteria below must be met):
(1)Absolute neutrophil count (ANC) **≥1.5×10⁹/L** without granulocyte colony-stimulating factor within 14 days; (2)Platelets **≥90×10⁹/L** without transfusion within 14 days; (3)Hemoglobin **>9 g/dL** without transfusion/recombinant erythropoietin within 14 days; (4)Total bilirubin ≤1.5×ULN; (5)AST/ALT ≤2.5×ULN (≤5×ULN allowed if liver metastases present); (6)Serum creatinine ≤1.5×ULN AND creatinine clearance (Cockcroft-Gault formula) **≥60 mL/min**; (7)INR or PT ≤1.5×ULN; (8)TSH within normal range; OR if abnormal, total T3 (or FT3) AND FT4 within normal limits; (9)Cardiac enzymes within normal limits (isolated abnormalities deemed clinically insignificant by investigator are allowed).
- For women of childbearing potential:
(1)Negative urine/serum pregnancy test within 3 days before Cycle 1 Day 1 (confirm equivocal urine tests with serum testing).
(2)Non-childbearing potential defined as:
- Postmenopausal (≥1 year amenorrhea), OR
- Surgically sterilized/hysterectomy. 10. All subjects (regardless of gender) at conception risk must use contraception with <1% annual failure rate during treatment and for 120 days after last dose.
Exclusion Criteria:
- Other malignancies within 5 years prior to first dose (excluding radically cured basal cell carcinoma, squamous cell carcinoma of skin, or carcinoma in situ).
- Current participation in interventional clinical trials or receipt of other investigational drugs/devices within 4 weeks before first dose.
- Prior therapy with:
<!-- -->
- Anti-PD-1/PD-L1/PD-L2 agents;
- Drugs targeting stimulatory/co-inhibitory T-cell receptors (e.g., CTLA-4, OX-40, CD137).
- Systemic administration of antitumor Chinese herbal medicines or immunomodulators (e.g., thymosin, interferon, interleukin) within 2 weeks (except localized use for pleural effusion).
- Active autoimmune disease requiring systemic treatment within 2 years (e.g., disease-modifying drugs, corticosteroids ≥10 mg/day prednisone equivalent, immunosuppressants).
- Exclusions: Hormone replacement (thyroxine/insulin/physiologic steroids);
- Known primary immunodeficiency;
- Isolated autoantibody positivity requires investigator confirmation of no autoimmune disease.
- Systemic glucocorticoids (excluding topical/inhaled) or immunosuppressive therapy within 4 weeks.Note: Physiologic-dose steroids (≤10 mg/day prednisone equivalent) permitted.
- Prior anti-angiogenic therapy (e.g., bevacizumab). 8. Active bleeding within 3 months prior to first dose:
- Hemoptysis (≥2.5 mL/fresh blood episode);
- Gastrointestinal bleeding. 9. High bleeding risk: Tumor invasion of major vessels or radiologist/investigator-assessed bleeding tendency.
- Major surgery within 4 weeks (excluding biopsy). 11. Severe unhealed wounds/ulcers/fractures. 12. Aspirin (>325 mg/day) or platelet-inhibiting NSAIDs for >10 consecutive days within 10 days prior to first dose.
- Full-dose anticoagulants/thrombolytics for >10 consecutive days within 10 days prior to first dose.Note: Prophylactic low-dose anticoagulants allowed:
(1)Warfarin ≤1 mg/day (INR ≤1.5); (2)Heparin ≤12,000 U/day; (3)Aspirin ≤100 mg/day. 14. Hereditary bleeding disorders, coagulopathy, or thrombotic history. 15. Clinically uncontrolled pleural effusion/ascites (asymptomatic/minimal fluid without drainage allowed).
- Allogeneic organ transplant (excluding corneas) or hematopoietic stem cell transplant.
- Hypersensitivity to sintilimab/bevacizumab or excipients. 18. Inadequate recovery from prior intervention toxicities (i.e., >Grade 1 or not returned to baseline, excluding alopecia/fatigue).
- HIV infection (HIV 1/2 antibody-positive). 20. Untreated active HBV:
- HBsAg-positive AND HBV-DNA > local ULN;
- Exceptions:
a. HBV-DNA <500 IU/mL with ongoing antiviral therapy; b. Anti-HBc (+) only with HBV-DNA monitoring. 21. Active HCV infection (HCV antibody-positive AND detectable HCV-RNA). 22. Live attenuated vaccines within 4 weeks prior to first dose. 23. Pregnancy or breastfeeding. 24. Uncontrolled systemic diseases, including:
- Severe uncontrolled cardiac arrhythmias (e.g., complete LBBB, ≥Grade II AV block, VT/AF);
- Unstable angina, CHF, NYHA Class ≥II heart failure;
- Arterial thromboembolism within 6 months (e.g., MI, stroke, TIA);
- Major surgery/unhealed wounds within 4 weeks; biopsy within 7 days (except IV catheterization);
- Uncontrolled hypertension (>140/90 mmHg);
- Active tuberculosis;
- Uncontrolled systemic infection;
- Clinical diverticulitis, intra-abdominal abscess, GI obstruction;
- Decompensated liver disease/active hepatitis;
- Uncontrolled diabetes (fasting glucose >10 mmol/L);
- Urine protein ≥++ AND 24-hr urine protein >1.0 g. 25. Psychiatric disorders impairing treatment compliance. 26. Any condition that may:
(1)Interfere with trial results; (2)Prevent full study participation; (3)Pose additional risks (per investigator judgment).
Quoted from ClinicalTrials.gov, NCT07328802, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07328802, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.